Access Official Technical PDF

Share Summary:LinkedInEmail

Biopharmaceutical manufacturing combines biological processes with demanding requirements for product quality, regulatory compliance and reliable supply. A 2017 report from Samsung BioLogics illustrates the operating model of a large contract manufacturing organization (CMO): customers provide manufacturing technology and product requirements, while the CMO develops the process at its facility, establishes its suitability for production and manufactures to contract. For automation engineers, system integrators and plant leaders, the model highlights how process execution, validation, documentation and capacity planning fit together in a regulated production environment.

How the biopharmaceutical CMO model works

Biopharmaceuticals such as therapeutic proteins are produced using technologies including genetic recombination and cell culture. Building dedicated manufacturing capacity requires substantial investment, while a drug’s eventual approval and sales are uncertain. Contract manufacturing allows pharmaceutical companies to outsource production rather than build every required facility themselves. The CMO, in turn, works to customer specifications and receives manufacturing technology that must be transferred into its own production environment.

This arrangement makes the relationship more than a simple exchange of product orders. The customer’s process, facility capabilities, production schedule, quality requirements and contract terms all have to align. The report describes an order-winning process that can take six to 12 months, including customer assessment, technical and commercial discussions, risk reviews, proposal development and contract negotiation.

Technology transfer and validation are central to scale-up

After a contract is signed, the customer transfers manufacturing technology to the CMO. One key objective is to minimize differences between the customer’s established process and the process implemented at the manufacturing site. The work then proceeds through production studies, including engineering runs and process validation runs, before the relevant product and manufacturing process are submitted for regulatory approval.

For plant and engineering teams, this sequence underscores why a successful transfer cannot be treated as a document handoff alone. The process must be executed under the receiving facility’s operating conditions, and the results need to demonstrate that manufacturing can proceed in a stable, controlled manner. The report does not specify particular automation platforms or control architectures; it does make clear that the production process and its supporting evidence must meet customer and regulatory expectations.

Upstream and downstream operations

The manufacturing process described includes an upstream stage, where cells are cultured to meet product specifications, and a downstream stage, where active pharmaceutical ingredients are refined. These stages form part of a broader production lifecycle that includes customer technology transfer, production runs, quality review and release.

Because biological production involves multiple process steps and product-specific requirements, coordination across manufacturing and quality functions is essential. The report states that customers can inspect the overall manufacturing process and request necessary measures. It also emphasizes that procedures and results must be documented and submitted to customers and regulatory authorities. In practice, this places disciplined recordkeeping and clear links between process execution and quality evidence at the center of plant operations.

GMP compliance shapes facility operations

Good manufacturing practice (GMP) requirements apply throughout production. The company’s report describes regulatory authorities inspecting manufacturing systems and quality controls at new facilities before granting product-specific manufacturing licenses. It records FDA and EMA approvals for Songdo Plant #2 in 2017, following earlier approvals associated with Plant #1.

For industrial automation stakeholders, the broader implication is that facility readiness involves more than installed production equipment. Processes must be operated consistently, quality controls must be demonstrable, and the organization must retain the documentation needed to support inspection and customer review. Equipment, procedures and production records therefore need to function as parts of a controlled operating system, even though the report does not detail the specific technical systems used.

Capacity planning must reflect actual production conditions

The report lists 182,000 liters of installed capacity across Plants #1 and #2: 30,000 liters and 152,000 liters, respectively. Plant #2 began operating in February 2016. A third plant, planned with 180,000 liters of capacity, was under construction during the reporting period, with operations targeted for the end of 2018. These figures describe the company’s plans and position as stated in the 2017 report, rather than current capacity.

Nominal capacity alone does not determine how much product a facility can make. The report explains that production capacity depends on factors such as production-cycle intervals, batch success rates and the number and characteristics of products being manufactured. It also notes that its standard capacity calculation included a 20% reserve at the commercial-production stage, while practical capacity accounted for additional operating factors. For 2017, the report gives a standard capacity of 260 batches, equivalent to 2.9 million liters, and production performance of 186 batches, equivalent to 1.62 million liters. It separately reports an average operating rate of 65.13%, calculated using practical production capacity.

For operations leaders, these distinctions matter when translating vessel volume into a production plan. Product mix, campaign timing, process requirements and operational performance affect achievable throughput. Capacity planning must therefore consider the characteristics of the manufacturing schedule, not just the total volume of installed equipment.

From contract manufacturing toward development services

The report also describes expansion beyond contract manufacturing into contract development organization (CDO) services. These services include cell-line development and process development for companies that do not have those capabilities internally. The company’s stated plans included strengthening development work and quality-analysis capability as it pursued a broader contract development and manufacturing organization model.

This direction brings development and production closer together in the service offering. It also reinforces the importance of managing the transition from process development to manufacturing, where customer requirements, production capability and quality controls must remain aligned.

Practical implications for industrial teams

The 2017 report illustrates several operational priorities for biopharmaceutical manufacturing teams:

  • Plan technology transfer deliberately. Align the customer’s process with the receiving facility and establish a clear path through engineering and validation runs.
  • Build compliance into daily operations. GMP expectations extend to process execution, quality controls, inspections and production documentation.
  • Use realistic capacity assumptions. Batch cycles, product characteristics and success rates influence practical throughput beyond nominal equipment volume.
  • Coordinate across functions. Manufacturing, quality, engineering and customer-facing teams all contribute to contract delivery and product release.

For automation and plant decision-makers, the central lesson is that scale is only one part of manufacturing capability. Reliable biopharmaceutical production depends on transferring processes effectively, demonstrating control through validation and documentation, and planning capacity around actual operating conditions. Those priorities provide a useful framework for evaluating facility readiness and production performance in a regulated CMO environment.

Access Official Technical PDF

About The Author